DBV Technologies (DBVT) EBT Margin (2020 - 2026)
DBV Technologies (DBVT) posted EBT Margin of 7171.43% for Q2 2026, down 36.17% sequentially from 5266.67% in Q1 2026, and down 438476.0% YoY from N/an in Q2 2025.
Powered by 
Analysis
DBV Technologies (DBVT) EBT Margin (2020 - 2026) Analysis & Trends
DBV Technologies has reported EBT Margin for 7 years, with the latest figure at 7171.43% in Q2 2026.
- Quarterly EBT Margin fell 438476.0% year-over-year to 7171.43% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 3491.11% (down 37947.0% YoY) and the FY2025 annual result came in at 2598.58%, up 11244.0% from the prior year.
- EBT Margin eased to 7171.43% in Q2 2026 per DBVT's latest filing, from 5266.67% in the prior quarter.
- Over five years, EBT Margin peaked at 3010.58% in Q4 2022 and troughed at 7171.43% in Q2 2026.
- A 5-year average of 2291.73% and a median of 1723.44% in 2022 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2022 and 2026: EBT Margin surged 347610 bps in 2022, then sank 438476 bps in 2026.
- Over 5 years, EBT Margin stood at 3010.58% in 2022, then slumped by 104 bps to 126.11% in 2023, then tumbled by 3158 bps to 4108.57% in 2024, then plunged by 68 bps to 6892.25% in 2025, then fell by 4 bps to 7171.43% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 7171.43%, 5266.67%, and 6892.25% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | DBV Technologies | 5.88 Bn | 5.70 Bn | - | -7,171.43% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -7,171.43% |
| Mar 31, 2026 | -5,266.67% |
| Dec 31, 2025 | -6,892.25% |
| Sep 30, 2025 | -1,195.53% |
| Jun 30, 2025 | -2,786.67% |
| Mar 31, 2025 | -3,387.50% |
| Dec 31, 2024 | -4,108.57% |
| Sep 30, 2024 | -2,839.74% |
| Jun 30, 2024 | -2,852.37% |
| Mar 31, 2024 | -1,940.09% |
| Dec 31, 2023 | -126.11% |
| Sep 30, 2023 | -705.56% |
| Jun 30, 2023 | -1,059.00% |
| Mar 31, 2023 | -937.15% |
| Dec 31, 2022 | 3,010.58% |
| Sep 30, 2022 | -833.51% |
| Jun 30, 2022 | -1,506.80% |
| Mar 31, 2022 | -652.75% |
| Dec 31, 2021 | -465.52% |
| Sep 30, 2021 | -1,816.55% |